Due to the more prevalent overexpression of cyclin D1 compared to other D-type cyclins in human cancers, development of selective IKKα inhibitors, also selective cyclin D1 inhibitors, may be beneficial for patients with specific types of lung cancer [66]. This evidence concerns the gene CCND1 and lung cancer.